These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28222788)

  • 21. Common antimicrobial resistance patterns, biotypes and serotypes found among Pseudomonas aeruginosa isolates from patient's stools and drinking water sources in Jordan.
    Shehabi AA; Masoud H; Maslamani FA
    J Chemother; 2005 Apr; 17(2):179-83. PubMed ID: 15920903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of quorum sensing-dependent virulence factor production and its relationship with antimicrobial susceptibility in Pseudomonas aeruginosa respiratory isolates.
    Karatuna O; Yagci A
    Clin Microbiol Infect; 2010 Dec; 16(12):1770-5. PubMed ID: 20132256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa from patients in a teaching hospital, Riyadh, Saudi Arabia, 2001-2005.
    Babay HA
    Jpn J Infect Dis; 2007 May; 60(2-3):123-5. PubMed ID: 17515646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple-locus variable number of tandem repeats (VNTR) fingerprinting (MLVF) and antibacterial resistance profiles of extended spectrum beta lactamase (ESBL) producing Pseudomonas aeruginosa among burnt patients in Tehran.
    Jabalameli F; Mirsalehian A; Sotoudeh N; Jabalameli L; Aligholi M; Khoramian B; Taherikalani M; Emaneini M
    Burns; 2011 Nov; 37(7):1202-7. PubMed ID: 21703769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distribution of serotypes and antibiotic resistance of invasive Pseudomonas aeruginosa in a multi-country collection.
    Nasrin S; Hegerle N; Sen S; Nkeze J; Sen S; Permala-Booth J; Choi M; Sinclair J; Tapia MD; Johnson JK; Sow SO; Thaden JT; Fowler VG; Krogfelt KA; Brauner A; Protonotariou E; Christaki E; Shindo Y; Kwa AL; Shakoor S; Singh-Moodley A; Perovic O; Jacobs J; Lunguya O; Simon R; Cross AS; Tennant SM
    BMC Microbiol; 2022 Jan; 22(1):13. PubMed ID: 34991476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evolution of antimicrobial resistance against Pseudomonas aeruginosa in a French university hospital between 2002 and 2006].
    Minchella A; Molinari L; Alonso S; Bouziges N; Sotto A; Lavigne JP
    Pathol Biol (Paris); 2010 Feb; 58(1):1-6. PubMed ID: 19875241
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Ruiz-Roldán L; Bellés A; Bueno J; Azcona-Gutiérrez JM; Rojo-Bezares B; Torres C; Castillo FJ; Sáenz Y; Seral C
    Biomed Res Int; 2018; 2018():8060178. PubMed ID: 29992165
    [No Abstract]   [Full Text] [Related]  

  • 28. Antimicrobial susceptibility and virulence genes of clinical and environmental isolates of
    Liew SM; Rajasekaram G; Puthucheary SA; Chua KH
    PeerJ; 2019; 7():e6217. PubMed ID: 30697478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
    McCracken M; Mataseje LF; Loo V; Walkty A; Adam HJ; Hoban DJ; Zhanel GG; Mulvey MR;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of clinical extensively drug-resistant Pseudomonas aeruginosa in the Hunan province of China.
    Li J; Zou M; Dou Q; Hu Y; Wang H; Yan Q; Liu WE
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):35. PubMed ID: 27215335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
    Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
    Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of Pseudomonas aeruginosa strains isolated from burned patients hospitalized in a major burn center in Tehran, Iran.
    Ranjbar R; Owlia P; Saderi H; Mansouri S; Jonaidi-Jafari N; Izadi M; Farshad S; Arjomandzadegan M
    Acta Med Iran; 2011; 49(10):675-9. PubMed ID: 22071644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa strains isolated from burn patients.
    Mirsalehian A; Feizabadi M; Nakhjavani FA; Jabalameli F; Goli H; Kalantari N
    Burns; 2010 Feb; 36(1):70-4. PubMed ID: 19524369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virulence attributes in Brazilian clinical isolates of Pseudomonas aeruginosa.
    Silva LV; Galdino AC; Nunes AP; dos Santos KR; Moreira BM; Cacci LC; Sodré CL; Ziccardi M; Branquinha MH; Santos AL
    Int J Med Microbiol; 2014 Nov; 304(8):990-1000. PubMed ID: 25127423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotype, antimicrobial susceptibility and clone distribution of Pseudomonas aeruginosa in a university hospital.
    Müller-Premru M; Gubina M
    Zentralbl Bakteriol; 2000 Jan; 289(8):857-67. PubMed ID: 10705618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.
    Walkty A; Adam H; Baxter M; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2018 Mar; 73(3):703-708. PubMed ID: 29244121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.
    Obritsch MD; Fish DN; MacLaren R; Jung R
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4606-10. PubMed ID: 15561832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa.
    Yamagishi Y; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Nakai H; Mikamo H
    Chemotherapy; 2017; 62(2):105-110. PubMed ID: 27788502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P; Hasçelik G; Unal S
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index.
    Milne KE; Gould IM
    J Antimicrob Chemother; 2010 Jan; 65(1):82-90. PubMed ID: 19861334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.